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SUMMARY 
Background - In many low and middle income countries the infectious disease tuberculosis 
is a leading and persistent cause of death, sickness and hardship. This is despite an effective 
and readily available treatment regimen. Better diagnostics and more rapid initiation of 
patients onto treatment is essential if the high burden of tuberculosis in these settings is to 
be substantially reduced, as there is currently no effective vaccine. There is an encouraging 
pipeline of improved diagnostic tools and algorithms being developed, some of which have 
been endorsed by the World Health Organization (e.g. Xpert MTB/RIF). These new 
diagnostic tools have the potential to overcome many of the weaknesses of the present 
processes, however they might substantially increase the demands on scarce resources and 
funds. In addition, whether these new diagnostics should replace existing methods or be 
used in combination with them is unclear. Before national tuberculosis programmes can 
scale-up new diagnostics, policy makers need to understand the effects on patients, the 
health system, and the wider population. Failure to do so could lead to poor performance 
outcomes, unsustainable implementation, and wasted resources. 
Methods - An innovative linked modelling approach is proposed that brings together 
detailed operational models of patient pathways with transmission models to provide the 
comprehensive projections required. The studies that make up this research first explore 
the concept of linked modelling, then in the second study develop a detailed operational 
model incorporating cost-effectiveness analysis. The third study uses the linked modelling 
approach to explore eight alternative diagnostic algorithms in Tanzania. It provides 
comprehensive projections of patient, health system and community impacts including 
cost-effectiveness analysis, from which the national tuberculosis programme can develop a 
strategy for scale-up of new diagnostics across the country. Having shown how the 
approach of linked operational and transmission modelling can assist policy makers, the 
fourth and fifth studies review the process of impact assessment and recommend how it 
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can be improved, and how the lessons from this research in tuberculosis diagnostics might 
apply to other health decisions in low and middle income countries.   
Findings - The linked modelling approach is feasible and relevant in supporting rational 
decision making for tuberculosis diagnostics in low and middle income countries.  The 
results from using the approach in Tanzania show that full scale-up of Xpert MTB/RIF is a 
cost-effective option with an incremental cost-effectiveness ratio of US$169 per DALY 
averted (95% credible interval, 104–265), and has the potential to significantly reduce the 
national tuberculosis burden. Substantial levels of funding would need to be mobilised to 
translate this into clinical practice. In the context of Tanzania, targeting Xpert MTB/RIF to 
HIV-positive patients only, was not cost-effective compared to rollout of LED fluorescence 
microscopy with two samples collected on the same day. Review of the Impact Assessment 
Framework and operational modelling used in these studies found the approaches had 
many other potential applications, for example for decisions around human parasitic 
disease diagnostics and tuberculosis treatment. 
Interpretation - In Tanzania full scale-up of Xpert MTB/RIF should be progressed in districts 
where resources and funding are available. LED fluorescence microscopy using two samples 
collected on the same day should be considered in other districts. Tuberculosis 
programmes should use the operational modelling approach to prioritise the 
implementation of new diagnostics by district. The operational and linked operational and 
transmission modelling approaches have many other potential applications in other 
contexts and disease areas and these should be further researched.   
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BACKGROUND 
Overview of Tuberculosis Worldwide in 2014 
The World Health Organization (WHO) estimates 1.5 million people died in 2014 as a result 
of Tuberculosis (TB), meaning that TB now ranks alongside human immune-deficiency virus 
(HIV) as the world’s leading cause of death from an infectious disease. 9.6 million 
individuals became sick with TB in 2014, of these 1.2 million were co-infected with HIV. The 
majority (85%) of TB cases reported are pulmonary TB.8     
Figure 1 – Trends in estimated global TB incidence and mortality 1990-20158 
Some improvements in TB incidence and mortality levels as a result of TB have been 
observed over the last 10 years (Figure 1), however the levels remain very high particularly 
in sub-Saharan Africa, the Indian sub-continent and some parts of Asia (Figure 2). In 
addition there has been a rise of drug resistant TB, in particular resistance to both isoniazid 
and rifampicin (known as multi-drug resistant TB (MDR-TB)) which is a growing concern in 
many parts of the world. 
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Figure 2 – Estimated TB incidence in 20148 
                         
It is essential that the barriers to prevention of infection, rapid case detection and initiation 
and completion of appropriate treatment are addressed if the global goals of reducing 
incidence and death rates from TB by 90% and 95% respectively are to be achieved by 
2035, as targeted by the WHO in the End TB strategy9. Critical to this is the availability and 
use of accurate and rapid diagnostics for TB and MDR-TB10; this is the focus and context of 
this body of research. 
TB Diagnosis and the patient pathway 
The most frequently used diagnostic tool in the developing world, where the burden of TB 
is highest, is sputum smear microscopy.  A typical diagnostic pathway for an individual who 
becomes sick with symptoms consistent with TB is shown in Figure 32. Once an individual 
has been identified as someone who may have TB and requires diagnostic testing (known 
as a presumptive TB case)11, they will be directed to a health facility where sputum will be 
collected. If smear microscopy is to be used as the diagnostic test, the individual will 
typically be asked to return the next day to provide a second sputum sample (in some 
countries a third sample may be required)12. The individual will then generally go home and 
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return at a later date to receive diagnosis. The sputum will be tested in a laboratory at the 
diagnostic facility where the turnaround time for tests is likely to be 1 to 3 days. 
 
Figure 3 Typical diagnostic pathway for an individual with pulmonary TB symptoms  
(e.g. Tanzania) 2 
A positive test will mean the individual is identified as a smear-positive (or bacteriologically 
confirmed) TB case. Treatment may be initiated immediately after a positive test, or the 
individual may be required to return another day (or to another facility) so that they, along 
with a supporter, can receive guidance on the importance of treatment adherence and 
monitoring. The supporter may be a member of the family or a community health worker 
whose role is to improve treatment adherence by observing the patient taking their 
medication daily. This process is known as Directly Observed Treatment (DOT)13 and helps 
to ensure patients complete the full course of treatment.  
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Some microscopy tests will be negative, but the individual will still exhibit TB symptoms. In 
these cases the individual will be asked to visit a facility that can conduct an X-ray and 
potentially will also be prescribed a short course of broad spectrum antibiotics. If 
symptoms persist and the X-ray is consistent with TB, the individual may be diagnosed by 
the clinician and initiated onto TB treatment – these are smear-negative (or clinically 
diagnosed) TB cases and represent around 42% of pulmonary TB cases worldwide8.  
TB cases typically return to the diagnostic centre or health clinic every 2 weeks for more 
drugs and treatment monitoring. At key intervals the monitoring will also involve sputum 
smear microscopy to assess treatment effectiveness (typically at 2 months, 5 months and 6 
months)14. 
For MDR-TB the diagnostic and treatment process is much longer. Diagnosis is likely to 
involve culture and drug sensitivity testing typically taking 6-12 weeks and if drug 
resistance is diagnosed the duration of treatment will extend to 18-24 months14.  
Issues associated with the diagnostic tools and the patient pathway for TB 
In the developing world individuals can often find it difficult and expensive to access 
diagnosis for TB15, 16. This results in delayed diagnosis and treatment initiation which risks 
transmission of TB to a larger circle of contacts17. Figure 3 illustrates where some patients 
drop out of the diagnostic or treatment process and become lost to follow up (LTFU). LTFU 
during the diagnostic process is critical as it results in many individuals with TB symptoms 
not starting on TB treatment and continuing to transmit the disease. Despite TB diagnosis 
and drug treatment usually being provided free (even in the poorest countries), the need 
for repeated visits to a diagnostic facility, hospital, or health clinic which may be many 
miles from home can result in significant and sometimes catastrophic costs for the 
individual18, 19. In this environment high levels of LTFU are common and account for 10-20% 
of the presumptive TB cases20.  
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There are principally two barriers associated with the most frequently used diagnostic tools 
and algorithms in high burden developing countries, such as those in sub-Saharan Africa. 
These are the accuracy of diagnosis and the time (and related patient cost) associated with 
completing the diagnostic process and starting treatment.   
Accuracy -  Boehme et al.21 observed in a study from 6 countries (Peru, Azerbaijan, Uganda, 
South Africa, India, and Philippines) that sputum smear microscopy had a 
sensitivity of 72.3% (69.2, 75.2) in HIV-negative individuals or when HIV status 
was unknown. This fell to 44.6% (37.7, 51.6) in HIV-positive individuals. 
Specificity was high at 100% (99.4, 100) for HIV-negative and unknown status, 
and 99.4% (99.1, 99.6) for HIV-positive status. These figures are consistent with 
systematic reviews22, 23. The low sensitivity of smear microscopy, particularly for 
HIV-positive individuals, leads to the high levels of clinically diagnosed TB. 
Without clinical diagnosis many individuals with active TB would not receive 
treatment. There is little published evidence on the accuracy of clinical diagnosis 
for TB, but where it does exist the evidence suggests that there are many cases 
where patients without TB are placed on TB treatment (false positive)24. This is 
partly due to the relatively low specificity of X-ray for TB.  A culture of the 
sputum is usually only ordered in sub-Saharan Africa if there is a high risk of 
MDR-TB. 
Time - The time from sputum collection to initiation of TB treatment for smear-positive 
cases will vary with individual and context. Boehme et al21 found a mean time of 
6.6 days with a median of 4 days. This time is in addition to the time an 
individual spends getting to the point where a TB test is ordered, which could be 
many weeks15. For smear-negative TB the delay in starting treatment is likely to 
be even longer, and in the Boehme et al21 study the mean time was 67 days and 
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the median 56 days. This delay and the frequent visits required to health 
facilities results in increased LTFU, continued transmission, extended morbidity 
and potentially high costs to patients15, 16, 20. 
TB diagnosis research 
Investment in research has resulted in promising new tools and modifications of existing 
algorithms for the diagnosis of TB and MDR-TB which could address the barriers of low 
accuracy and delays to diagnosis. For example, the WHO have endorsed in recent years the 
use of LED fluorescence microscopy25, same day sputum collection26, Xpert MTB/RIF 
(Xpert)27, Line Probe Assay (LPA) 28, liquid culture approaches (e.g. MGIT 960)29 and most 
recently in very restricted cases a lateral flow urine lipoarabinomannan assay (LF-LAM)30. 
Xpert in particular has had a big influence on TB control programmes since first being 
endorsed by the WHO in 201131, primarily for HIV-positive patients and those with 
suspected drug resistance. This endorsement has since been broadened and now includes 
all adults and children suspected of having pulmonary and extrapulmonary TB27.  
 
Figure 4: Assay Procedure for Xpert MTB/RIF32 
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Xpert is a molecular assay (see Figure 4) that can identify Mycobacterium tuberculosis and 
resistance to one of the key drugs used in standard treatment, rifampicin. Trials of Xpert 
have shown improved accuracy and accelerated time to appropriate diagnosis in 
comparison to smear microscopy21. Many countries are looking to rollout Xpert, and South 
Africa33 in particular has achieved greatest coverage. However concerns about the cost of 
the device and test cartridges has been a barrier to wider implementation in some 
countries. In addition, there are other issues such as the need for a reliable power supply, 
questions on where to site the devices and which cases to target, that have delayed scale-
up. There are improvements to Xpert and many other new diagnostic tools that are 
currently under development and testing, for example the Xpert Ultra cartridge, Genedrive 
MTB/RIF, TBDx and TB LAMP10. 
Impact Assessment for new TB diagnostic tools and algorithms 
The WHO has focused on obtaining robust data on test accuracy and using a systematic 
approach (GRADE)34 to appraise and develop guidelines for implementation of new tools. 
However, many authors have indicated that more work is needed to go beyond test 
accuracy in order to promote rational, evidence-based decision-making on scale-up and 
implementation35, 36.  
An impact assessment framework (IAF)6 (Table 1) to support decision making on new 
diagnostics by linking evidence on inputs to outcomes was proposed, followed by further 
calls for more work beyond accuracy37.  This recognises that decision-makers need a lot 
more information than just the scientific performance of a test in idealistic conditions. They 
also need to understand the operational and pragmatic impacts of implementation in 
combination with existing and other new tests. There has also been recognition that new 
TB diagnostics are not implemented in isolation, but are always part of an algorithm that 
operates in conjunction with other diagnostic approaches, such as clinical judgement or 
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radiology39. Policy makers choosing between diagnostic strategies need evidence on what 
is the best combination of tools for their context, which tools should be used for which 
patients and whether the new tools replace or are used in combination with existing tools. 
A flexible, practical and rapidly implementable methodology is needed which is applicable 
to developing countries and usable by the TB control community within different health 
systems. This could then be used to evaluate impact on patients, health systems and the 
wider community in order to provide evidence to support national policy decisions. This is 
where computer based decision analytic modelling can assist, but the approach needed 
must take account of the local operational and epidemiological context to be most useful. 
Table 1 – The Impact Assessment Framework (IAF)6 
 
Modelling TB diagnostic algorithms 
Computer based decision analytic modelling is increasingly being used in the developed 
world to evaluate alternative health care technologies40, 41. Frequently this includes taking 
into account budget constraints alongside projecting resource needs and health outcomes. 
Layer of 
Assessment 
Example questions that need addressing in understanding 
impacts of new diagnostics for TB 
Layer 1: 
EFFECTIVENESS 
ANALYSIS 
How well does the new tool work in terms of accuracy?  
How many additional cases will be identified? 
How many additional cases will actually start treatment? 
What will happen to the time from presentation to starting treatment? 
Layer 2: 
EQUITY ANALYSIS 
Who benefits from the new tool? (e.g. poor/less poor, adults/children) 
Why do these benefits accrue? (e.g. change time to issue of results)  
Layer 3: 
HEALTH SYSTEM 
ANALYSIS 
What are the human resource implications? 
What are the infrastructure implications? 
Layer 4:   
SCALE-UP 
ANALYSIS 
What are the projected impacts of going to scale with the new tool? e.g. 
a) cost savings to patients in relation to income 
b) cost savings to health providers / the health system 
c) effects on transmission 
Layer 5:   
POLICY ANALYSIS 
What other similar technologies are available or likely to become 
available? 
How do similar existing or emerging technologies compare?  
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The approach can bring together global experience of new technologies with detailed 
national or provincial data to provide policy makers with the evidence they need to support 
rational decisions.  
Modelling of TB has in the past focused mainly on high level dynamic epidemiological 
models of disease transmission42-45. These models typically project incidence, prevalence 
and mortality outcomes of interventions, but do not take account of the local patient 
pathways and operational constraints that exist within all health systems and especially in 
developing countries. In order to promote rational, evidence-based decision-making on 
implementation it is vital for national policy makers to consider and evaluate the health 
system process in relation to TB diagnosis and to have projections on the performance of 
the health system, health system budgets and patient impacts. The operational modelling 
approach (discrete event simulation46, 47 or DES) used extensively in the developed world to 
model proposed changes in health care facilities48 and other environments such as 
manufacturing processes49 and retail outlets50, could potentially provide the missing level 
of detail required by national TB policy makers in developing countries. DES is a very 
flexible approach that could be used to address many policy related questions like those 
proposed by the IAF. It would enable patient pathways to be modelled in detail, including 
each significant event a patient experiences within the pathway. Interaction with staffing 
and other patients that result in queuing and potential bottlenecks47would be modelled. In 
DES there are five key elements that make up the model, these are: 
1.  Entities representing people or objects moving around a process (e.g. patients, samples) 
2.  Attributes associated with entities (e.g. age, gender, HIV status)   
3.  Queues representing waiting areas for entities (e.g. waiting rooms) 
4.  Activities where actions take place (e.g. sputum collection). 
5. Resources required to complete an activity (e.g. laboratory technician) 
10 
 
If an operational DES model of the patient pathways to diagnosis and treatment could be 
linked with an epidemiological model of the transmission dynamics of TB, then all the key 
patient, health system and transmission impacts of changes in diagnostic technology and 
algorithms could potentially be projected. Data collated from the context of interest could 
be used to populate the model and would enable many of the questions posed in the IAF 
(Table 1) to be addressed to support policy decisions in the context of interest.  
The research studies 
This portfolio of research studies contributes to original knowledge by exploring the 
feasibility and use of the new and innovative approach of linked operational and 
transmission modelling to support the selection and implementation of new tuberculosis 
diagnostic tools in the developing world1, 3. For the first time, an operational model of 
patient pathways incorporating cost-effectiveness analysis is used to study alternative TB 
diagnostics in sub-Saharan Africa2. The linked modelling approach is used to evaluate the 
scale-up of new diagnostic algorithms in Tanzania providing a methodology and the 
information required by the national TB programme to develop a comprehensive strategy 
for new TB diagnostics3. The modelling approach is reviewed to see if it might be used in 
other disease areas such as human parasitic diseases4. Finally, alongside additional studies 
carried out by the author in Brazil and Ethiopia, the Impact Assessment Framework is 
reviewed5.   
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SUMMARY OF STUDIES 
Linking the Publications 
The five studies in this body of research are linked to each other and two earlier studies as 
shown in Figure 5. The two earlier publications by Mann et al. 6 (Paper A) and Squire et al.7 
(Paper B), in part inspired the five publications described (Papers 1 to 5). Paper A6 proposed 
an Impact Assessment Framework (IAF) for tuberculosis diagnostics as a tool to generate 
the questions that policy makers need to consider about which new diagnostic algorithms 
to implement.  Paper B7 identified the need for a new approach to address many of these 
questions. 
 
 N.B. Grey boxes refer to the publications for the studies submitted in this thesis. The white boxes 
refer to two publications that in part inspired this overall body of work.   
Figure 5 – Linking the publications  
 
Paper 11 develops the innovative concept of linked operational and transmission modelling 
of tuberculosis mentioned in paper B7 to address many of the issues raised by the IAF for 
TB diagnostics described in paper A6. Paper 22 describes and uses an operational model of 
TB diagnostics for the first time in the developing world, to demonstrate that many of the 
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national policy issues for the Tanzanian context could be addressed by using such an 
approach. Paper 33 uses linked operational and transmission modelling with national and 
district TB data to assess the impacts of eight optional diagnostic algorithms in the 
Tanzanian context. It provides detailed patient, health system and community projections, 
including incremental cost-effectiveness measures, to draw conclusions on the scale-up of 
new diagnostic algorithms for TB in Tanzania. Paper 44 draws on the evidence from papers 
22 and 33 to consider whether the operational modelling approach might be appropriate to 
guide scale-up and implementation of new diagnostics for human parasitic diseases. Paper 
55 discusses how the IAF proposed in paper A6 might be improved, based on the evidence in 
paper 33 and from other uses of the IAF by the author in Brazil and Ethiopia.  Table 2 shows 
the main focus for each study and how they compare.  
Table 2 – Main focus of the five studies 
 
Each study is summarised individually below. 
Study Context focus Disease Area Operational 
Modelling 
Linked 
Operational & 
Transmission 
Modelling 
Type of 
paper 
1 Developing world 
with data sourced 
from Tanzania and 
Malawi 
TB and MDR-
TB diagnostics 
Yes Yes Conceptual 
2 Dar es Salaam and 
Kilimanjaro in 
Tanzania 
TB diagnostics Yes – 
primary 
focus 
Discussed Technical – 
modelling 
paper 
3 Tanzania scale-up TB diagnostics Yes Yes Policy 
development 
 
4 Developing world Diagnostics for 
Parasitic 
disease 
 
Yes - Primary 
focus 
Discussed Review 
5 Developing world 
with data from 
Tanzania, Ethiopia 
and Brazil 
TB and MDR-
TB diagnostics 
and  
treatment 
Discussed Discussed Review  
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Study 1 -  A modelling framework to support the selection and implementation of 
new tuberculosis diagnostic tools1. 
Primary Objective: To propose a new and effective modelling concept to support national 
policy decisions on TB diagnostics by providing comprehensive projections of impact for 
alternative tools and algorithms relevant to the national context.   
Journal: Internal Journal of Tuberculosis and Lung Disease  
Target Audience: Global and national TB programmes and those involved in TB research in 
developing countries 
Method:  Projecting the impact of new diagnostic tools and algorithms requires estimates 
of patient benefits, health system effects and impacts on disease transmission that are 
relevant to the context under consideration. Since these effects are all interrelated a model 
which could link detailed operational simulation of health systems with a transmission 
model of the national epidemiology was considered appropriate. This methodology is 
innovative and would potentially provide an approach that could inform national decision 
making. To test the concept, two independent model components were first developed 
and then linked as follows:- 
Operational model – A detailed discrete event simulation (DES) was developed to reflect 
the diagnostic pathways for presumptive TB cases from sputum collection, through 
laboratory testing, and onto appropriate treatment based on the WHO guidelines51. 
Diagnostic algorithms for new and retreatment presumptive TB cases were represented in 
the model. Sample collection and sputum examination by microscopy at the diagnostic 
centre and in the reference laboratory were modelled in detail. The WITNESS modelling 
software (http://www.lanner.com/en/witness.cfm) for DES was used to develop the model 
and produce the projections. 
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Transmission model - The transmission modelling component for this study was based on a 
differential equation model that captured the most important features of the natural 
history of TB and was developed at the National Taiwan University by Dr Hsien-Ho Lin. As 
with many TB transmission models52, 53 states for susceptible, latently infected, infectious, 
and recovered were included. To incorporate the health system context where the 
diagnostic tool would be employed, the usual active disease states of the model were 
extended to include details of the pathway from disease onset to TB diagnosis and 
initiation of treatment. The extended transmission model provided a platform to 
systematically understand how the improved test characteristics of new tools could be 
translated into population impact on transmission of TB.  
Linked operational and transmission model - The operational and transmission model 
components were linked by using outputs of one model to serve as inputs into the other. 
For example, the incidence of TB is an output of the transmission model; this informs the 
input into the operational model through the number of TB presumptive cases coming for 
diagnosis in the health system. Similarly, the average time to receive diagnosis is an output 
of the operational model which effects the duration of infectiousness, which therefore 
becomes an input into the transmission model (Table 3). Information collected from 
Tanzania and Malawi was used to calibrate the linked model. 
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Table 3. List of inputs into and outputs from the operational and transmission models. 
 
Results: The potential impact of a new generic diagnostic with improved sensitivity, a 
shorter laboratory processing time and reduced sample requirements was compared with 
standard smear microscopy using the linked model. The results of the linked model showed 
the alternative diagnostic strategy reduced the average time to diagnosis (∼60%), nearly 
eliminated the fraction of presumptive TB cases lost to diagnostic follow-up, and increased 
the number of patients accessing treatment (∼20%). The transmission model component 
projected that the alternative diagnostic scenario may result in a more rapid decline in TB 
incidence. The rate of reduction in incidence (compared to the base case) would increase 
over time (∼1% in Year 1, ∼3% in Year 5 and ∼6% in Year 10). These results demonstrated 
some of the effects different diagnostic tools may have on key outcomes, and illustrated 
the feasibility of a linked modelling approach.   
Input Output
Average number of TB presumptive cases coming for 
diagnosis per diagnostic centre per day Average time to receive diagnosis
Proportion of Tests Smear Positive Lost to Follow-Up (Diagnostic default)
Treatment times Number of visits to diagnostic centre
Number of microscopy staff at diagnostic centre Diagnosis Outcomes
Lab time per sample Treatment outcomes
Staff shift patterns Time to complete treatment
Physician availability Default in treatment
Probability of default during diagnostic and treatment 
pathways Number of samples processed
Transport availability for samples Health System Costs
Unit costs Patient Costs
Output Input
TB incidence Transmission rate
TB prevalence Primary progression rate
Reactivation rate
Natural cure rate
TB-specific mortality
Diagnostic Test Performance - Sensitivity
Lost to Follow-Up (Diagnostic default)
Duration parameters (e.g., from symptom onset 
to health center visit, from seeking diagnosis to 
reciving diagnosis)
TB treatment parameters (e.g., fraction of initial 
defaulters, treatment success rate, treatment 
failure and death rate) 
TRANSMISSION MODEL
OPERATIONAL MODEL
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Study 2 -  Modelling the impact of new diagnostic tools for tuberculosis in 
developing countries to enhance policy decisions2. 
Primary Objective: To describe and demonstrate how a discrete event simulation (DES) 
model of the detailed patient pathways to TB diagnosis could be integrated with a cost-
effectiveness analysis to enhance policy decisions on new diagnostics in developing 
countries 
Journal: Health Care Management Science 
Target Audience: Management Science community involved in Health Care research 
Method: The IAF was used to postulate the questions that policy makers in developing 
countries would need to address in order to decide which of the available diagnostic tools 
for TB were most appropriate for a given context. In order to address these questions an 
operational model linked to a transmission model (as described in study 1) would be 
required to address the patient, health system and community questions. This study was 
primarily focused on the operational model used to project patient and health system 
impacts. The study used data from two very different diagnostic centres in Tanzania (an 
urban centre in Dar es Salaam and a rural centre in Kilimanjaro). Patient pathways for 
presumptive TB cases and individuals being treated for TB were mapped based on these 
two centres. The sputum sample pathways were also mapped through the laboratory 
process. A DES of the health system was developed using the WITNESS modelling software 
encompassing these patient and sputum sample pathways. The visual WITNESS 
representation of these pathways is shown in Figure 6.  
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The developed model was used to project the impacts of three optional diagnostic 
algorithms compared to a base case of Ziehl Neelsen microscopy (ZN). The optional new 
algorithms were light emitting diode fluorescence microscopy (LED), and two alternative 
algorithms for placement and use of automated nucleic acid amplification tests (aNAAT) 
such as Xpert MTB/RIF54. The impact on health system costs was included in the analysis 
and an incremental cost-effectiveness ratio (ICER)55 calculated to compare 
implementations of the alternative algorithms in the two districts in Tanzania. 
Results: The results of the operational model demonstrated that in the urban centre in Dar 
es Salaam significant improvements in TB diagnosis could be delivered through optimising 
sputum smear microscopy by implementing LED. In this resource constrained setting, an 
estimated 5.0 % increase in TB cures could be delivered at very low investment. If more 
finance were available, implementation of aNAAT could be cost-effective in both Dar es 
Salaam and Kilimanjaro. The model demonstrated that the benefit of aNAAT in the number 
of patients cured would be up to 15.8 % in Dar es Salaam and 25.3 % in Kilimanjaro. These 
benefits would accrue not just from an increase in the number of patients started on TB 
treatment, but also from earlier case detection, reduced diagnostic LTFU and a reduction in 
false positive diagnoses by increasing the proportion of cases bacteriologically confirmed. 
Comparing results between the two diagnostic centres indicated that the benefits and cost-
effectiveness vary between settings. Five cost-effective strategies were identified for the 
rollout of new diagnostics. These ranged from only implementing LED in Dar es Salaam 
(ICER - US$1 per disability adjusted life year (DALY) averted) at an incremental cost of less 
than US$1,000 per year, through to full rollout of aNAAT in both centres (ICER - US$65 per 
DALY averted at an incremental cost of nearly US$80,000 per year). 
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Study 3 –  Assessment of the patient, health system, and population effects of 
Xpert MTB/RIF and alternative diagnostics for tuberculosis in Tanzania: 
an integrated modelling approach3. 
Primary Objective: To predict the impact and cost-effectiveness in Tanzania of the scale-up 
of Xpert as a diagnostic tool for TB under alternative targeting scenarios and in comparison 
to current practice and other microscopy based diagnostic algorithms.    
Journal: The Lancet – Global Health 
Target Audience: Health care researchers and TB programmes working in the developing 
world with particular interest in diagnostics. 
Method: Following the methodologies described and tested in the first two studies, this 
study assessed the scale-up effects in Tanzania of different diagnostic algorithms for TB at 
the patient, health system, and population levels, using a modelling platform that 
integrated operational and transmission modelling components as shown in Figure 7.  
 
Figure 7: Linked operational and transmission modelling3 
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The operational component2 used the DES approach and incorporated patient and sputum 
sample pathways based on WHO guidelines and the present diagnostic procedures in 
Tanzania. The model was calibrated using data from two diagnostic centres in Tanzania 
(Temeke and Kibong’oto). The transmission component followed previous dynamic 
epidemiological modelling approaches and incorporated the care seeking pathway of 
patients with TB56. The model was calibrated to the epidemiological situation of 
tuberculosis in Tanzania. Cost-effectiveness analyses were completed to compare eight 
different diagnostic options including ZN Microscopy, LED microscopy with two alternative 
sputum sample collection strategies, Xpert full scale-up and four alternative algorithms to 
target Xpert at HIV-positive and/or smear-negative presumptive TB cases. The incremental 
cost of implementing each alternative diagnostic option over the base case of ZN 
microscopy was derived from the Tanzanian health system perspective, and included the 
additional annual running costs (e.g. consumables, drugs, equipment maintenance, and 
laboratory personnel) and the investment costs (e.g., microscopes and the equipment 
related to Xpert implementation). The introduction of new tuberculosis diagnostics is 
expected to improve the survival of patients co-infected with HIV, therefore the 
incremental costs of additional antiretroviral therapy (ART) on the basis of the projected 
number of deaths from tuberculosis and HIV co-infection were estimated. The population 
effect on tuberculosis epidemiology was summarised using DALYs57. Uncertainty and 
sensitivity analysis was also performed.  
Results: Comprehensive projections for all the major outcomes were produced at patient 
level (e.g. likelihood of treatment and cure, time to start treatment, and number of visits to 
diagnostic facilities), health system level (e.g. staffing requirements, number of tests, anti-
retroviral treatments for HIV (ART) and additional costs) and community level (e.g. TB 
incidence, prevalence and mortality, and HIV prevalence). Three cost-effective strategies in 
the context of Tanzania were identified: full scale-up of Xpert at an ICER of US$169 per 
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DALY averted; followed by LED microscopy with two samples collected on the same day 
(Same-day LED) at US$45 per DALY averted; and LED fluorescence microscopy with two 
samples collected on different days at US$29 per DALY averted. Figure 8 shows for each 
diagnostic algorithm (represented by the circles), the projected additional costs to the 
health service (X-axis), and the average cost-effectiveness ratio (ACER) (Y-axis). The ACER is 
the cost-effectiveness ratio compared to ZN microscopy rather than the ICER which 
compares to the next best alternative strategy. The size of the circle is proportional to the 
benefits in DALYs averted for each option. This shows, for example that full Xpert scale-up 
(B1) has the greatest benefit in DALYs averted (largest circle), but also the highest 
additional cost. Same-day LED (A3) and targeted Xpert to HIV-positive cases with additional 
HIV testing (B3) have similar benefits in DALYs averted, but Same-day LED is significantly 
less costly and therefore more cost-effective (lower on the Y axis).  
 
Figure 8 – Intervention impact - Sustainability vs. Cost-Effectiveness vs. DALYs averted. 
  
Note: The circles represent each diagnostic option. A2: LED microscopy with two samples on different days; 
A3: Same-day LED; B1: full scale-up of Xpert; B2: Xpert for known HIV-positive presumptive TB cases only; 
B3: as B2, but with additional HIV testing to increase proportion of presumptive TB cases that know their 
HIV status; C1: Xpert for smear-negative, HIV-positive presumptive TB cases only; C2: as C1,  but with 
additional HIV testing to increase proportion of presumptive TB cases that know their HIV status. 
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Study 4 – Operational modelling to guide implementation and scale-up of 
diagnostic tests within the health system: exploring opportunities for 
parasitic disease diagnostics based on example application for 
tuberculosis4. 
Primary Objective: To review the operational modelling approach used to support decisions 
on diagnostics for TB and consider whether the approach could provide useful insights to 
support implementation of new diagnostic innovations for human parasitic diseases.  
Journal: Parasitology 
Focus: Health care programmes and researchers working in the developing world with 
particular interest in diagnostics for human parasitic diseases. 
Method: Decisions on new diagnostics for any disease require the comparison of different 
strategies that consider the technical characteristics of the tools, how these tools will be 
implemented within a health system, and the likely effects on outcomes and costs. 
Operational modelling to assess the potential impact of new diagnostic strategies on health 
system costs, infrastructure, patient access and outcomes has been used to assist in policy 
decisions on TB diagnostics3. Such an approach has not previously been deployed for 
parasitic diseases58. In Study 4 the approach used for TB modelling is described and then, 
with reference to the literature, the opportunities for use to assist in policy decisions on 
new diagnostics for human parasitic diseases such as malaria59, schistosomiasis60, and 
human African trypanosomiasis (HAT)61 are considered.  
Results: Operational modelling of TB diagnostics in Tanzania has provided valuable insight 
to help policymakers understand context-specific impacts of new tools and algorithms. The 
approach has been used to assist the TB programme in the development of a national 
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strategy on the use of a new molecular test (Xpert)2, 3. In addition, the approach has helped 
assist in important decisions concerning diagnosis of MDR-TB in Brazil5 and South Africa62.  
These experiences from TB and a review of published material and comments from experts 
in parasitic disease diagnostics, suggest there are potential useful applications of 
operational modelling for policy decisions on diagnostics for human parasitic diseases. For 
example, the arrival of rapid diagnostic tests (RDTs) and molecular genotyping for diseases 
such as malaria59, HAT61 and schistosomiasis60. With the new diagnostic opportunities 
comes an ever increasing set of complex decisions on which diagnostic to use, in which 
context and how to incorporate them into the existing diagnostic algorithms. Modelling the 
potential impacts of these opportunities, including cost-effectiveness would provide a 
useful decision support tool. For example, fluorescent microscopy and molecular test loop-
mediated isothermal amplification (LAMP) have been developed for HAT. There is the 
potential for a complicated diagnostic algorithm to ensue involving these new and existing 
tools. Modelling of the diagnostic pathway for each tool could help to identify how best to 
integrate diagnostics in the pathway, and increase effective uptake of these novel tests. It 
was concluded that operational modelling as used in assisting policymakers address the 
issues with new TB diagnostics, could usefully be applied to the diagnostic challenges of a 
number of human parasitic diseases.  
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Study 5 – Developments in Impact Assessment of New Diagnostic Algorithms for 
Tuberculosis Control5. 
Primary Objective: To review the Impact Assessment Framework (IAF) as a tool to support 
TB programmes and researchers based on experience of its use in Brazil and Ethiopia.  
Journal: Clinical Infectious Diseases 
Focus: Global and national infectious disease programmes and researchers working in the 
developing world with particular interest in TB and MDR-TB diagnosis and treatment. 
Method: The IAF6 was developed in 2010 by a multi-disciplinary team to provide a 
framework to indicate what information should ideally be collected, in a systematic 
manner, for new diagnostic tools and approaches for TB to assist in policy decisions. Study 
5 reviewed the use of the IAF in Brazil where it had been used as an integral part of an 
implementation trial of new diagnostics63, and in Ethiopia where it had been used 
conceptually as a training tool for staff in the TB programme. The experiences of using the 
IAF in these two different contexts was considered alongside experiences from modelling 
TB diagnostics in other low and middle income countries (LMIC) such as Tanzania1,2,3 to 
discover what lessons could be learnt and how the IAF might be improved to enhance 
understanding and use.  
Results: The IAF was found to be an effective tool in both the implementation trial in Brazil 
and in the Ethiopian training programme. In the implementation trial it assisted in the 
design phase to ensure that data collection covered all the areas required to assist in policy 
decisions. Members of the study team had their thinking challenged and this helped to 
avoid misperception and missing key information required for the analysis phase. For 
example, in collecting data on both health system and patient impacts (Layers 2 and 3). In 
the analysis phase, this comprehensive data collection enabled evidence for scale-up, and 
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policy analysis (Layers 4 and 5) to be performed. This went beyond what could purely be 
provided from a diagnostic accuracy trial, for example by enabling the impact of rollout of 
Xpert as a frontline tool for diagnosis to be considered, as well as for drug susceptibility 
testing as used in the trial.  
The conceptual testing of the IAF in the Ethiopian training programme received positive 
feedback from attendees. The greatest benefits were in defining a comprehensive set of 
research questions needed to provide the evidence on impact to support policy decisions in 
Ethiopia. Having arrived at the questions, it was then possible to define how the data could 
be collected and the analysis tools required to address the questions (e.g. health economic 
tools, patient pathway mapping, and operational modelling). The main lessons from the 
review were:- 
1. The IAF should be reconfigured to emphasise that equity should be at the centre of 
the evaluation and to show how data from the Effectiveness, Patient and Health 
System layers feed into Scale-up and Policy Analysis (renamed Horizon Scanning) 
(Figure 9). 
2. A methodology to synthesize and present the broader evidence from an impact 
assessment study is required.  Operational modelling as used in the study in 
Tanzania3 would be an effective methodology that could enable projections and 
synthesis of results and outcomes.  
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Figure 9 – Revised presentation of the Impact Assessment Framework5 
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DISCUSSION 
Main findings  
Prior to Study 1 much of the research on TB diagnostics had focused on measures of the 
sensitivity and specificity of new tools22, 64 and on demonstration projects of these tools65. 
These studies are essential to the evaluation of new tools, but do little to help understand 
impacts on the operation of the health system, patient effects and the knock on impacts on 
transmission of the disease from new diagnostic algorithms.  
The concept of linked operational and transmission models to compare the potential 
overall effects of different tools and algorithms was first demonstrated in Study 1. The 
study showed, using two simple alternative diagnostic strategies, how the test 
characteristics of diagnostic tools (e.g., sensitivity and number of specimens required for 
diagnosis) have an effect on important epidemiological parameters (e.g., LTFU during 
diagnosis and thus the average duration of infectiousness). Similarly, changing 
epidemiological parameters (e.g., TB incidence) affects the demand on health systems (e.g., 
number of presumptive TB cases requiring diagnostic services). In many settings, detailed 
knowledge of patient, specimen and information flows, including bottlenecks, may not be 
well understood. Operational models demonstrate why these logistical issues are 
important for predicting the effectiveness of diagnostic tools. Sensitivity and uncertainty 
analysis can be used to identify which unknown operational components are most 
important to measure. In study 1 the feasibility of the linked modelling approach was 
demonstrated. The approach was found to be flexible and could be used to assess many 
different options (e.g., different tools and different ways of using those tools within the 
health system). The model could be adjusted to reflect specific epidemiological situations 
and health system infrastructures.  
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Policy makers need to simultaneously consider the existing infrastructure and capabilities, 
the local epidemiology and what future diagnostic tools may be in the pipeline, before 
committing to a particular decision. The linked modelling approach can assist in these 
decisions and could be particularly important as local policy makers grapple with the 
rapidly expanding list of diagnostic recommendations from the WHO10.  
Study 2 focused particularly on the operational component of the linked modelling 
approach and added a health economic assessment.  The study used data from two 
diagnostic districts in Tanzania (Dar es Salaam and Kilimanjaro) with different HIV 
comorbidities, capacities, current diagnostic tools and population densities (urban and 
rural).  The study found that operational modelling using DES could provide useful 
projections of the effects on the health system, running costs, and patient outcomes of 
alternative TB diagnostic strategies in the diagnostic centres of Tanzania. An incremental 
cost-effectiveness analysis using the outputs from the modelling approach found cost-
effective implementation scenarios across the two districts for aNAAT based on Xpert. 
Depending on the available funds different implementation scenarios would be more 
effective. So the operational modelling approach allowed decision makers to understand 
the true opportunity cost of different options by reflecting on the budgetary constraints. 
For example, with unlimited funds full scale-up in both sites was cost-effective, but if funds 
were restricted to less than US$30,000 per year (either due to budgetary constraints or 
other health intervention opportunities being more cost-effective) then scale-up of aNAAT 
for all presumptive TB cases in Kilimanjaro and implementation of LED microscopy in Dar es 
Salaam would be the most effective use of funds. The flexibility of the DES modelling 
approach enabled policy makers in Tanzania to consider specific sites and algorithms for 
trialling the new aNAAT technology. This study proposed that using the same modelling 
approach, an overall assessment of the impacts of scale-up of alternative diagnostic 
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algorithms using aNAAT across the 168 diagnostic districts of Tanzania could be performed 
and linked to a disease transmission model (Study 3).  
Policy advisers in Tanzania recognised the benefits of the modelling approach and 
requested to use the DES themselves to evaluate alternative diagnostic strategies in the 
future. This request led to a pilot study conducted in 2014.  The visual and interactive 
capability of the operational modelling tool enabled national policy makers to assist in 
validation, identify new strategies to investigate, and engage with the modelling process 
and the outputs. As proposed in study 1, this study confirmed that where possible the DES 
should be linked to a disease transmission component to enhance predictions and to 
provide outputs on important factors such as TB incidence, which in turn impact health 
system and patient outcomes. 
Study 3 built on the first two studies by taking the linked operational and transmission 
modelling approach proposed, developing a model to represent all districts in Tanzania, 
and using the linked model to deliver comprehensive projections of impact for eight 
alternative diagnostic algorithms for TB if scaled-up across the whole of Tanzania. No study 
had previously been so comprehensive and modelled so many outcomes including patient, 
health system, community and cost-effectiveness measures in a single study. Focussing on 
the cost-effectiveness outcomes which are derived from the projections at patient, health 
system and community levels, three alternative cost-effective scale-up strategies for the 
initial diagnosis of TB in the context of Tanzania were identified: -  
1. Xpert as a replacement for microscopy at US$169 per DALY averted 
2. Same-day LED microscopy at US$45 per DALY averted 
3. LED microscopy with two samples on different days at US$29 per DALY averted. 
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The analysis showed that in Tanzania (and probably countries with similar health systems 
and TB epidemiology) targeting Xpert to be used only for HIV-positive or high MDR-TB risk 
presumptive cases, or targeting only to smear-negative HIV-positive cases, was not cost-
effective compared with scale-up of Xpert, or use of Same-day LED fluorescence 
microscopy for all presumptive TB cases (i.e. irrespective of HIV status). This result was 
different to the WHO recommendation for the targeted use of Xpert at the time31. This 
WHO recommendation has since been modified and is now consistent with the findings of 
this study27. The reason for the inferior cost-effectiveness of targeted implementation to 
HIV-positive presumptive TB cases is that the projected gains in DALYs averted are the 
same or lower than those projected from implementing Same-day LED fluorescence 
microscopy, and the projected costs are substantially higher. There are a number of 
reasons for this outcome, principally these are:- 
 Most HIV-positive individuals do not know their HIV status at the point of TB 
diagnostic testing in Tanzania, therefore targeting only to known HIV-positive 
presumptive TB cases will always mean many HIV-positive individuals do not 
receive the new improved diagnostic tool.  
 Even in a high HIV prevalent setting like Tanzania the majority of presumptive TB 
cases are HIV-negative. Excluding HIV-negative patients from using a more 
effective test has a disproportionate effect on DALYs averted, particularly as the 
life expectancy of HIV-negative individuals is longer than HIV-positive individuals.  
 Additional ART costs of surviving HIV-positive TB cases results in higher additional 
costs per patient for an HIV-positive TB cure compared to an HIV-negative TB cure. 
These results do not suggest that access to Xpert should be denied to the HIV-positive 
infected population. In fact, as indicated above, full scale-up of Xpert is the only way to 
ensure all HIV-positive patients receive Xpert diagnosis in the context of Tanzania.  
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Two diagnostic algorithms that targeted Xpert to smear-negative cases were also modelled. 
These were not cost effective compared to the other algorithms modelled, principally 
because by adding an additional test to microscopy resulted in increased diagnostic lost to 
follow-up, delayed diagnosis for a number of individuals, and incurred significantly higher 
costs than, for example, Same-day LED. 
Important to the concept of cost-effectiveness is that the intervention must be affordable 
and sustainable. So for example, the projected 10-year incremental cost to the TB 
programme of Xpert scale-up (US$28·3 million) represents an increase of about 25% in 
funds to the present TB programme. It is interesting to note that a large proportion of 
these additional costs (38%) relate to the treatment of MDR-TB patients diagnosed as a 
result of resistance to rifampicin being detected as part of the Xpert assay. This is despite 
Tanzania being a low prevalence setting for MDR-TB. In addition, the HIV programme 
would incur incremental costs of US$8·6 million as a result of the additional cost of ART. 
Without a major ongoing injection of funds into the Tanzanian TB programme, the full 
scale-up of Xpert appears unsustainable. Therefore the programme would be well advised 
to consider scaling up Xpert in some districts with available funds whilst implementing 
other cost-effective, but less costly interventions, in other districts such as Same-day LED. 
The findings of this study were compared with two other studies published on the cost-
effectiveness of Xpert, namely Vassal et al66 and Menzies et al67. Vassal estimated the ACER 
of Xpert compared to a base case of ZN microscopy to be US$52–138 per DALY averted, 
using decision analytical models of tuberculosis in India, South Africa, and Uganda. In 
another calibrated, dynamic mathematical model of five southern African countries 
(Botswana, Lesotho, Namibia, South Africa, and Swaziland), Menzies reported the ACER of 
Xpert to be US$959 (95% CrI 633–1485) per DALY averted. This compares to an ACER of 
US$109 (95% CrI 72–144) per DALY averted in Study 3.  In addition to the expected 
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difference in ACER due to different epidemiology of TB and HIV in the different settings, the 
studies are not directly comparable as only Study 3 includes such a comprehensive 
assessment. For example, the projected impact on transmission and the effect of additional 
ART costs are not included in Vassal; the long term impact on improved life expectancy in 
Menzies only includes the impact up to a maximum of 10 years; and the impacts of 
operational bottlenecks in the health system are only included in Study 3. These differences 
demonstrate the potential importance of these additional factors, and suggest that Study 3 
is the most comprehensive of the published studies on cost-effectiveness of Xpert at the 
date of publication.  
The key findings from Study 3 demonstrated the value of the modelling approach in the 
assessment of TB diagnostics. Study 4 considered whether such an approach might be 
useful for the assessment of impact of other new diagnostic technologies appropriate to 
human parasitic diseases. Impacts on patients, health systems and the scarce financial and 
human resources in LMIC are critical to the successful implementation of new diagnostic 
tools and algorithms in these disease areas. The review concluded that using data from 
existing diagnostic tools for parasitic diseases, alongside the results from trials of new 
diagnostics, to populate operational models would enable the patient and health system 
impacts to be projected. This would provide comparisons of the alternative options and 
assist in identifying the priorities that support policy decisions.  
The IAF as proposed by Mann et al6 was useful in defining the key questions that policy 
makers needed addressing to assist in decisions in relation to new TB diagnostic 
implementation. Study 5 was able to draw lessons from the IAF’s use in studies in Ethiopia 
and Brazil, and also from the use of linked modelling in Study 3 in Tanzania3, to extend and 
reconfigure the IAF. It identified how operational modelling could assist in addressing the 
key questions. The IAF was also seen as a useful framework to assist researchers and policy 
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makers in other areas outside diagnostics for TB. For example, in the training program in 
Ethiopia it was successfully applied to a decision around ambulatory treatment for MDR-TB, 
suggesting that the approach has wider application than initially considered.  
    
Study limitations  
There are limitations in the modelling approach, for example all modelling studies 
inevitably require assumptions on some of the input parameters. Complete data are rarely 
available and some simplification of the process is necessary to make a model useable. This 
is true of the modelling studies discussed here as it is of all such studies, although due to 
the more detailed operational component, data requirements may be higher than some 
other modelling studies. Where important data were unavailable assumptions were 
explicitly made using published research. The effect of these assumptions was tested in 
Study 3 using uncertainty analysis. Overall, the estimated ICERs were robust to uncertainty 
of most input variables and the ranking of diagnostic options remained unchanged. 
In order to achieve the results projected in these studies the programme will need to make 
a number of local infrastructural changes, such as increased availability of robust power 
supplies. Modelling analysis can cost these interventions, but cannot account for all the 
practical challenges that might arise from implementation of a new method such as Xpert. 
Programmes need to consider these as a separate matter.  
Studies 2 and 3 focused on modelling new TB diagnostics in Tanzania where there is 
currently a low MDR-TB prevalence amongst TB cases (1% of TB cases). For this reason the 
impact of drug-resistant TB transmission was not included. It was assumed that MDR-TB 
would remain at the same level relative to drug susceptible TB within this context.  This 
may mean there is an underestimate of the cost-effectiveness of Xpert because the use of 
Xpert could reduce the transmission of MDR-TB through increased and earlier identification 
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of rifampicin resistance. When modelling countries with higher MDR-TB prevalence (see 
Figure 10) including a component for the transmission of MDR-TB could be beneficial.  
 
Figure 10 – Percentage of new TB cases with MDR-TB – 2014 estimate8 
Impact on patient costs and reducing the number of TB cases experiencing catastrophic 
costs, is an important consideration for future new diagnostic approaches, particularly 
bearing in mind the END TB strategy of the WHO9. These costs have not been included in 
these studies, although the supplementary appendix to Study 368 does illustrate how this 
could be included in future studies by collecting data on the costs incurred by patients for 
each health facility visit. This would enable the model to project the costs accrued by 
patients along the alternative diagnostic and treatment pathways. 
The new IAF described in study 5 will sometimes raise questions where the evidence 
required is unavailable or too expensive to gather. In addition, by the time results are 
available new questions may arise that were not considered relevant at the start of an 
investigation. Despite these limitations, the new IAF is a useful guide to assist policy makers 
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in gathering broad evidence to support policy decisions on TB diagnostic algorithms and 
potentially other decisions areas (e.g. ambulatory or hospital treatment of MDR-TB). 
 
Study strengths  
The linked operational and transmission modelling approach used in studies 1 and 3 is 
innovative and comprehensive. It allows the evaluation and projection of key outcomes 
that policy makers need to consider in order to make decisions not just on new diagnostic 
technologies for TB, but also where to place them in the diagnostic algorithm.  Critical to 
such an analysis is not just the impact from increased bacteriologically confirmed cases, but 
also the impact on clinically diagnosed cases through empirical diagnosis as highlighted by 
Theron et al69. These empirically diagnosed cases are an important aspect of these studies 
that have rarely in the past received this attention. The studies project the health system, 
patient and community impacts as well as a detailed cost-effectiveness analysis. All these 
aspects have rarely if ever previously been combined in any published study.  
The application of operational modelling described in papers 1, 2, 3 and 4 is new to health 
projects in LMIC. Using a detailed DES approach has enabled interactions and bottlenecks 
in the health system to be considered. The visual representation (e.g. Figure 6) of the 
modelled patient pathways engages policy makers, researchers, and programme staff in 
validating the model and understanding the outcomes. This approach has coined a new 
phrase, Virtual Implementation70, 71, which many other countries are now using to assess 
implementation of new TB diagnostics including Ethiopia, South Africa and the 
Philippines72. So far there have been no studies applying the operational modelling 
approach to human parasitic disease diagnostics as proposed in Study 4, however studies 
using operational modelling to assist in decisions around blood transfusion services in 
Ghana, MDR-TB treatment trials in Ethiopia and oxygen needs for childhood pneumonia in 
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Gambia73 have been progressed. This illustrates the wide application of the modelling 
approach to LMIC. 
These studies have involved a multi-disciplinary approach (including modellers, clinicians, 
laboratory staff, programme managers and health economists) from multiple countries 
(United Kingdom, Taiwan, USA, Brazil and Tanzania) alongside national TB programme staff 
from countries with a high burden of TB such as Tanzania, Malawi, Ethiopia and Brazil. This 
has facilitated comprehensive and robust evaluation of the approaches. The studies have 
involved working with national policy makers with influence and a commitment to 
delivering improved services to people often living in poverty who experience many 
barriers to accessing effective health services.  In Tanzania this has resulted in the 
development of a strategy for the scale-up of new diagnostics as well as building local 
capacity to model new alternative diagnostic strategies in the future. 
Study 5 brings the research full circle by going back to an initial reference that inspired 
study 16. In so doing, lessons from the intervening research were captured and revisions to 
the IAF proposed that could enhance its utility.   
  
Study implications         
The implications of the studies described in this document can be divided into three areas:- 
1. Implications for TB diagnostics in Tanzania 
 For Tanzania, the integrated modelling approach predicts that full scale-up of Xpert 
is a cost-effective option for TB diagnosis and has the potential to substantially 
reduce the national burden. It also estimates the level of funding that will need to 
be mobilised to translate this into clinical practice. As there are likely to be 
insufficient funds available to scale-up Xpert as the primary TB test across the 
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country, policy makers should consider Same-day LED as an alternative in some 
centres until funds become available for the wider scale-up of Xpert. The 
operational modelling component and the new IAF can be used to help assess 
which centres should be scaled-up first and to evaluate new diagnostic tools as 
they become available.  
2. Implications for the modelling of TB diagnostics 
 The results from the linked operational and transmission modelling of TB 
diagnostics in these studies are based on the epidemiology and TB health system of 
Tanzania. However, in similar sub-Saharan African countries with similar 
epidemiology and decentralised health systems for TB, the conclusions are likely to 
be similar.  This linked approach used for Tanzania should be adapted and 
replicated in other countries with a high burden of TB to inform policy. Such an 
approach is currently underway in Addis Ababa in Ethiopia and Cavite province in 
the Philippines.  
3. Implications for projecting impacts of health system interventions in LMIC 
 These studies have shown the utility of an operational modelling approach to 
policy decisions on TB diagnostics. Study 4 outlines how the approach could be 
used to assist policy decisions in the area of diagnostics for human parasitic 
diseases such as malaria. Study 5 has shown how the IAF used for TB diagnostics 
might be applied to other decisions on health interventions such as the decision on 
whether to use ambulatory or hospital care for MDR-TB treatment. The implication 
is that the IAF and the modelling approach is likely to be a useful support to policy 
decisions for many major health interventions in LMIC, particularly where there are 
multiple and uncertain impacts. The IAF is a useful tool to understand the questions 
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that need addressing. Operational and linked operational and transmission 
modelling is a useful approach to projecting the answers to these questions.   
 
Future studies  
Apart from applying the approach to new country contexts and other disease areas, future 
studies using the approach for assessment of TB diagnostic algorithms should consider 
inclusion of patient cost data and projections for MDR-TB transmission. The End TB 
strategy9 outlines the importance of these two areas. Firstly in “reducing the proportion of 
TB-affected families facing catastrophic costs due to TB to zero by 2020”. Secondly in the 
“early diagnosis of TB including universal drug susceptibility testing, and systematic 
screening of contacts and high-risk groups” alongside “treatment of all people with TB 
including drug resistant TB”. In addition, the End TB strategy emphasises the need for 
“research to optimize implementation and impact; and promote innovations”, the 
modelling approach described here is an effective way to help achieve this.   
Future studies should seek to build the capacity within national TB programmes to conduct 
high quality research using the modelling approach as discussed here. This has been 
successfully piloted in Dar es Salaam and Addis Ababa by the author. Further studies in 
other countries should make this a priority especially as new diagnostics are continually 
being developed and opportunities to move diagnostics closer to where patients initially 
seek medical help are likely to be available in the future. The impact of such approaches 
will need evaluation and quantification to support policy decisions.  
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CONCLUSIONS 
National policy makers for TB need more than simple sensitivity and specificity information 
to address key questions on scale-up of new technologies and algorithms. A linked 
operational and transmission modelling approach can help to address many of the gaps in 
knowledge that policy makers have on impact covering important areas affecting patients , 
health systems and communities. The same approach can provide cost-effectiveness 
measures to enable policy makers to compare health inventions. In Tanzania the approach 
has shown full scale-up of Xpert for TB diagnosis would provide significant benefits and is 
cost-effective, but is currently unaffordable as a national strategy. The alternative of 
targeting Xpert to HIV-positive or smear-negative presumptive TB cases is not cost-effective 
when compared with Same-day LED. For Tanzania the preferred strategy is to implement 
Xpert in all diagnostic districts (where the infrastructure is suitable) for initial TB diagnosis 
of pulmonary TB as a replacement for smear microscopy in as many areas as the 
programme can afford. Same-day LED should be considered elsewhere until funds become 
available for Xpert. The impact assessment framework and the operational modelling 
approach, which have been key elements of this research, have potential to assist policy 
makers in assessing many other health interventions in TB and other disease areas in LMIC. 
These opportunities should be further researched and explored.   
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